101140 — InBioGen Co Cashflow Statement
0.000.00%
Last trade - 00:00- KR₩79bn
- KR₩80bn
- KR₩6bn
Annual cashflow statement for InBioGen Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 94,125 | -119,687 | 18,857 | 16,122 | -1,419 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | -101,259 | 107,843 | -23,597 | -20,022 | -2,762 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1,052 | -1,099 | 2,465 | 2,809 | -1,737 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -7,069 | -11,505 | -1,051 | -33.1 | -5,554 |
| Capital Expenditures | -2,402 | -331 | -331 | -84.3 | -42.5 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -38,035 | -15,594 | 138 | 10.1 | 509 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -40,437 | -15,925 | -193 | -74.2 | 466 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 61,543 | 13,568 | -1,957 | -265 | 273 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 14,038 | -13,862 | -3,201 | -373 | -4,815 |